Found: 27
Select item for more details and to access through your institution.
Editorial: type 1 diabetes, microscopic colitis and the need to explore the complex mechanisms of this association—authors' reply.
- Published in:
- 2023
- By:
- Publication type:
- Editorial
Letter: delays to diagnosis of IBD—Challenges requiring a systematic approach.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 57, n. 12, p. 1477, doi. 10.1111/apt.17521
- By:
- Publication type:
- Article
Letter: Albumin—Does formulation matter?
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 57, n. 12, p. 1482, doi. 10.1111/apt.17531
- By:
- Publication type:
- Article
Letter: histologic disease activity and colorectal neoplasia risk.
- Published in:
- 2023
- By:
- Publication type:
- Letter to the Editor
Editorial: composite kidney outcomes in studies with patients with cirrhosis and AKI—Are we ready to "MAKE" the switch?
- Published in:
- 2023
- By:
- Publication type:
- Editorial
Letter: delays to diagnosis of IBD—Challenges requiring a systematic approach. Authors' reply.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 57, n. 12, p. 1479, doi. 10.1111/apt.17548
- By:
- Publication type:
- Article
Letter: Albumin—Does formulation matter? Authors' reply.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 57, n. 12, p. 1484, doi. 10.1111/apt.17546
- By:
- Publication type:
- Article
Letter: histologic disease activity and colorectal neoplasia risk—authors' reply.
- Published in:
- 2023
- By:
- Publication type:
- Letter to the Editor
Review article: Functional dyspepsia and pregnancy—Effects and management in a special population.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 57, n. 12, p. 1375, doi. 10.1111/apt.17534
- By:
- Publication type:
- Article
Editorial: optimal combination of non‐invasive tests to determine significant fibrosis in non‐alcoholic fatty liver disease—authors' reply.
- Published in:
- 2023
- By:
- Publication type:
- Editorial
Editorial: proactive anti‐TNF drug monitoring in IBD—Ready for prime time?
- Published in:
- 2023
- By:
- Publication type:
- Editorial
Editorial: optimal combination of non‐invasive tests to determine significant fibrosis in non‐alcoholic fatty liver disease.
- Published in:
- 2023
- By:
- Publication type:
- Editorial
Editorial: the other bug.
- Published in:
- 2023
- By:
- Publication type:
- Editorial
Editorial: proactive anti‐TNF drug monitoring in IBD—Ready for the prime time? Authors' reply.
- Published in:
- 2023
- By:
- Publication type:
- Editorial
Clinical significance and impact of gastric non‐Helicobacter pylori Helicobacter species in gastric disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 57, n. 12, p. 1432, doi. 10.1111/apt.17488
- By:
- Publication type:
- Article
Editorial: golimumab dosing intensification effective in ulcerative colitis with no need for therapeutic drug monitoring—author's reply.
- Published in:
- 2023
- By:
- Publication type:
- Editorial
Meta‐analysis: The efficacy of therapeutic drug monitoring of anti‐TNF‐therapy in inflammatory bowel disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 57, n. 12, p. 1362, doi. 10.1111/apt.17313
- By:
- Publication type:
- Article
Issue Information.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 57, n. 12, p. 1359, doi. 10.1111/apt.17013
- Publication type:
- Article
Editorial: type 1 diabetes, microscopic colitis and the need to explore the complex mechanisms of this association.
- Published in:
- 2023
- By:
- Publication type:
- Editorial
Risk of colorectal neoplasia according to histologic disease activity in patients with inflammatory bowel disease and colonic post‐inflammatory polyps.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 57, n. 12, p. 1445, doi. 10.1111/apt.17495
- By:
- Publication type:
- Article
Editorial: in the era of effective antiviral therapy, long‐term dynamic endoscopic monitoring does not seem to be necessary for all CHB patients with compensated cirrhosis.
- Published in:
- 2023
- By:
- Publication type:
- Editorial
Letter: practical considerations for nonselective beta‐blocker therapy in portal hypertension.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 57, n. 12, p. 1475, doi. 10.1111/apt.17482
- By:
- Publication type:
- Article
Type 1 diabetes and microscopic colitis: A nationwide matched case–control study in Sweden.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 57, n. 12, p. 1423, doi. 10.1111/apt.17473
- By:
- Publication type:
- Article
Long‐term endoscopic surveillance in HBV compensated cirrhotic patients treated with Tenofovir or Entecavir for 11 years.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 57, n. 12, p. 1407, doi. 10.1111/apt.17463
- By:
- Publication type:
- Article
The combination of the enhanced liver fibrosis and FIB‐4 scores to determine significant fibrosis in patients with nonalcoholic fatty liver disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 57, n. 12, p. 1417, doi. 10.1111/apt.17472
- By:
- Publication type:
- Article
Longer time to recovery from acute kidney injury is associated with major adverse kidney events in patients with cirrhosis.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 57, n. 12, p. 1397, doi. 10.1111/apt.17457
- By:
- Publication type:
- Article
Editorial: golimumab dosing intensification effective in ulcerative colitis with no need for therapeutic drug monitoring.
- Published in:
- 2023
- By:
- Publication type:
- Editorial